CRISPR/Cas9-mediated COL7A1 editing in induced pluripotent stem cells from patients with recessive dystrophic epidermolysis bullosa

被引：0
|
作者：
Izmiryan, A. [1 ,2 ]
Lefort, N. [1 ,2 ]
Hovnanian, A. [1 ,2 ,3 ]
机构：
[1] Inst Imagine, INSERM, U1163, Paris, France
[2] Univ Paris Descartes Sorbonne Cite, Paris, France
[3] Hop Necker Enfants Malad, Dept Genet, Paris, France
来源：
HUMAN GENE THERAPY | 2017年 / 28卷 / 12期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P143
引用
下载
收藏
页码：A57 / A57
页数：1
相关论文
共 50 条
  • [1] CRISPR/Cas9-mediated correction of two recurrent COL7A1 mutations in primary and induced pluripotent stem cells from patients with recessive dystrophic epidermolysis bullosa
    Izmiryan, A.
    Berthault, C.
    Hovnanian, A.
    HUMAN GENE THERAPY, 2019, 30 (11) : A175 - A175
  • [2] CRISPR/CAS9-MEDIATED CORRECTION OF TWO RECURRENT COL7A1 MUTATIONS IN PRIMARY AND INDUCED PLURIPOTENT STEM CELLS FROM PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
    Izmiryan, Araksya
    Berthault, Camille
    Hovnanian, Alain
    ACTA DERMATO-VENEREOLOGICA, 2020, 100 : 50 - 50
  • [3] COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa
    Hainzl, Stefan
    Peking, Patricia
    Kocher, Thomas
    Murauer, Eva M.
    Larcher, Fernando
    Del Rio, Marcela
    Duarte, Blanca
    Steiner, Markus
    Klausegger, Alfred
    Bauer, Johann W.
    Reichelt, Julia
    Koller, Ulrich
    MOLECULAR THERAPY, 2017, 25 (11) : 2573 - 2584
  • [4] Crispr/Cas9-based COL7A1 editing for recessive dystrophic epidermolysis bullosa
    Izmiryan, A.
    Bovolenta, M.
    Mavilio, F.
    Hovnanian, A.
    HUMAN GENE THERAPY, 2015, 26 (10) : A27 - A27
  • [5] Predictable CRISPR/Cas9-Mediated COL7A1 Reframing for Dystrophic Epidermolysis Bullosa
    Kocher, Thomas
    March, Oliver Patrick
    Bischof, Johannes
    Liemberger, Bernadette
    Hainzl, Stefan
    Klausegger, Alfred
    Hoog, Anna
    Strunk, Dirk
    Bauer, Johann Wolfgang
    Koller, Ulrich
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (10) : 1985 - +
  • [6] CRISPR/Cas9-mediated gene correction of COL7A1 in dystrophic epidermolysis bullosa
    Hainzl, S.
    Kocher, T.
    Murauer, E. M.
    Larcher, F.
    Steiner, M.
    Bauer, J. W.
    Koller, U.
    HUMAN GENE THERAPY, 2016, 27 (11) : A144 - A144
  • [7] Ex vivo COL7A1 editing via CRISPR/Cas9 in recessive dystrophic epidermolysis bullosa
    Hainzl, S.
    Peking, P.
    Kocher, T.
    Murauer, E.
    Larcher, F.
    Duarte, B.
    Steiner, M.
    Bauer, J.
    Reichelt, J.
    Koller, U.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S92 - S92
  • [8] CRISPR/Cas9 and Homology Directed Repair-mediated correction of COL7A1 recurrent mutations in induced pluripotent stem cells from patients with recessive dystrophic epidermolysis bullosa
    Izmiryan, A.
    Berthault, C.
    Hovnanian, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (09) : S264 - S264
  • [9] Biallelic COL7A1 editing in iPSCs via CRISPR/Cas9 for recessive dystrophic epidermolysis bullosa mutations
    Jackow, J.
    Guo, Z.
    Abaci, H.
    Doucet, Y.
    Shin, J.
    Hansen, C.
    Salas, J.
    Christiano, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S135 - S135
  • [10] Non-Viral Gene Editing Therapy for Recessive Dystrophic Epidermolysis Bullosa: CRISPR/Cas9 Mediated COL7A1 Exon 80 Excision
    Wang, Xianding
    Li, Yinghao
    Saez, Irene Lara
    Wang, Wenxin
    TISSUE ENGINEERING PART A, 2023, 29 (13-14)
12345